Related Experiment Videos
Percutaneous transseptal balloon mitral valvuloplasty: the Chinese experience in 30 patients
1Department of Cardiology, Guangdong Provincial Cardiovascular Institute, Guangzhou, China.
Abstract:
The results of percutaneous transseptal balloon mitral valvuloplasty (PTBMV) in 30 Chinese patients with rheumatic mitral stenosis are reported. PTBMV with the Inoue balloon catheter was successfully performed in 27 patients without any significant complications. The mean left atrial pressure decreased from 20.15 +/- 6.75 to 7.06 +/- 4.54 mm Hg (p less than 0.001); mitral valve gradient decreased from 16.86 +/- 6.37 to 2.68 +/- 2.96 mm Hg (p less than 0.001); pulmonary systolic pressure decreased from 48.38 +/- 17.57 to 30.04 +/- 11.49 mm Hg (p less than 0.001); mitral valve area increased from 1.27 +/- 0.31 to 2.13 +/- 0.43 cm2 (p less than 0.001). Results of follow-up examinations at 8 to 20 months showed that both subjective and objective improvement was well maintained. PTBMV is a highly effective and safe nonsurgical method of relieving mitral stenosis.
Insights
Percutaneous transseptal balloon mitral valvuloplasty (PTBMV) effectively treated rheumatic mitral stenosis in Chinese patients. This nonsurgical method provided significant, lasting improvement without major complications.
Area of Science:
- Cardiology
- Interventional Cardiology
- Valvular Heart Disease
Background:
- Rheumatic heart disease remains a significant cause of mitral stenosis globally.
- Surgical mitral valve replacement carries risks, necessitating alternative treatments.
Purpose of the Study:
- To evaluate the efficacy and safety of percutaneous transseptal balloon mitral valvuloplasty (PTBMV) in Chinese patients with rheumatic mitral stenosis.
Main Methods:
- PTBMV was performed using the Inoue balloon catheter in 30 patients.
- Hemodynamic parameters and valve area were assessed before and after the procedure.
Main Results:
- Successful PTBMV was achieved in 27 patients with no significant complications.
- Significant improvements were observed: decreased left atrial pressure, mitral valve gradient, and pulmonary systolic pressure (p < 0.001).
- Mitral valve area significantly increased from 1.27 +/- 0.31 to 2.13 +/- 0.43 cm2 (p < 0.001).
Conclusions:
- PTBMV is a highly effective and safe nonsurgical treatment for rheumatic mitral stenosis.
- Subjective and objective improvements were well-maintained during 8-20 months of follow-up.